Resources
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 225
Change in PEPFAR Supported PrEP Initiations
Official characterizations of the HIV response as “doing very good” warrant a closer look at the data. AVAC’s analysis of PEPFAR prevention figures shows PrEP initiations declined 41% in one year, with women and men each seeing drops exceeding 50%. Data on key populations remains unavailable.
Potential Lenacapavir Supply, 2026-28
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
Prevention Option:
10 Minutes with JPIDS
Senior Program Manager of Cure Advocacy, Jessica Salzwedel, is featured on the Journal of Pediatric Infectious Disease Society podcast discussing a recent publication on the ethics of pediatric HIV cure research.
Prevention Option:
AVAC Year in Review 2025
This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization.
Prevention Option:
Sexually Transmitted Infections: ‘Self-testing’ versus ‘self-collection’: the critical role of consistent language in the field of STI diagnostics
This editorial from AVAC’s Alison Footman and colleagues makes the case for precise and consistent language around self-testing and self-collection. because clarity impacts policy, expectations, and access.
Prevention Option:
AVAC Input for Recompetition of the NIAID HIV/AIDS Clinical Trials Networks
AVAC’s formal input submitted on the re-competition of the NIAID HIV/AIDS Clinical Trials Networks. The recommendations were informed by the People’s Research Agenda (PRA), a comprehensive framework developed through consultations with over 130 community representatives across 23 countries.
Prevention Option:
Supporting RECs/IRBs to Review the Enrolment of Pregnant/Lactating Individuals in HIV Prevention Trials using International Ethical Guidance
Appearing in the journal Research Ethics, this article written by AVACer Breanne Lievense and partners provides ethics recommendations to be included in future research on pregnant and lactating individuals.
Manifestations and Lived Experiences of Structural Racism for Racial and Ethnic Minority Communities Affected by HIV Across the United States
Structural racism shapes the lived experiences of racial and ethnic minority communities through political disempowerment, inequitable access to resources, and intergenerational trauma. This study provides support for the argument that the HIV and COVID-19 epidemics will not be adequately addressed without urgent action on the various ways in which structural racism manifests in the US.
Prevention Option:
The Real-World Impact of Defunding STI Research
The US presidential administration’s funding cuts and policy shifts are reshaping the public health landscape in profound ways. While many of these changes have drawn significant media attention, the impact on sexually transmitted infection research and prevention has remained largely overlooked, though the consequences are dire, writes AVAC’s Alison Footman writes in TheBodyPro.
LEN Generics — Can we go faster?
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
Prevention Option:
showing 1-10 of 225